Navigation Links
MoleSafe USA Expands Services to Leading Cancer Facilities at St. Joseph's/Candler and CentraState Medical Center
Date:5/26/2010

MILLBURN, N.J., May 26 /PRNewswire/ -- MoleSafe (www.molesafe.com), the world's most advanced melanoma screening program, announced today that it will offer its services at two of the nation's top medical centers by the end of 2010.  The following institutions will soon offer in-house MoleSafe clinics to provide their patients with cutting-edge skin cancer detection:

  • The Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler (Savannah, Georgia)
  • CentraState Medical Center (Freehold, New Jersey)

"We could not be more proud to align MoleSafe with these highly regarded medical centers that have each done so much to save and improve the lives of skin cancer patients.  The rapid growth and expansion of MoleSafe is a promising sign that Americans are continuing to become better educated on the very serious threat posed by melanoma, a disease that needlessly takes the lives of thousands of people each year," said Dr. Richard Bezozo, president of MoleSafe USA.

The adoption of MoleSafe by these leading cancer facilities follows the recent announcement that MoleSafe is offered at the renowned NYU Ronald O. Perelman Department of Dermatology in New York.  Launched in the U.S. in 2008, MoleSafe has expanded rapidly throughout the United States.  In addition to its medical center partnerships, MoleSafe operates stand-alone clinics in San Francisco, California; Charlotte, North Carolina; Albuquerque, New Mexico; and Millburn, New Jersey.

In addition to his role as president and founder of MoleSafe USA, Dr. Richard Bezozo is the lead blogger for "Melanoma Updates", a blog that details the latest developing information and technology on skin cancer prevention and detection. (www.melanomaupdates.com)

MoleSafe is part of an international network of forty melanoma screening centers located primarily in Australia and New Zealand, which have the highest rates of melanoma.  Using advanced technology developed by MoleMap New Zealand, Ltd, this network of clinics has conducted more than 135,000 examinations on 75,000 patients, imaged and diagnosed in excess of 1.5 million lesions, identifying close to 1,500 melanomas.

The MoleSafe four-pronged procedure represents a new standard of care and is part of a life-long program for the early detection of melanoma. It has four key elements:

  • Risk assessment: Using its database, MoleSafe has developed a risk assessment model that can help identify patients who may be at higher risk of melanoma;
  • Serial Digital Dermoscopy: Individual moles are imaged microscopically, and tagged to their location on the body for subsequent diagnosis, identification and comparison over time;
  • Diagnosis and Management: The patient's complete skin record, including digital images and clinical information, is sent via a secure tele-dermatology network to MoleSafe's panel of world-class melanoma dermatologists (dermoscopists) for analysis and reporting. Patients and their designated doctors receive their reports and their digital melanogram.
  • Education and Follow-up: The MoleSafe melanographer, a trained nurse, nurse practitioner or physician assistant educates patients about the risks of sun exposure, and helps generate a continuing partnership between MoleSafe, the patient and his/her doctor.  

To schedule an appointment for a MoleSafe screening at any one of these new locations, call 877-MOLESAFE (877- 665-3723).

About MoleSafe

MoleSafe (www.molesafe.com) is a state-of-the-art procedure involving the digital imaging, archiving and diagnosis of moles and other suspicious lesions. The procedure utilizes a combination of high resolution dermoscopy imaging technology that uses high intensity light to penetrate through the surface of the skin to show the structure of moles (and other lesions) and a dermatologist's expert evaluation of the images. In addition to the increased diagnostic accuracy associated with dermoscopy, MoleSafe is able to detect at an earlier stage any new, changing and/or suspicious lesions by monitoring and comparing the images over time. While MoleSafe has the ability to identify all skin cancers, its primary focus is on the early detection of melanoma.


'/>"/>
SOURCE MoleSafe
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Waters Expands Xevo MS Instrument Platform With Next-Generation Mass Spectrometers
2. West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund
3. Connectyx Retains Services of CP Capital Securities as It Expands Its Presence in the $5 Billion US Electronic Health Record Market
4. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
5. Eye-Fi Expands Hotspot Access Service Worldwide
6. MyPunchbowl Expands Leadership Team With Veterans of Evite.com and Pizza Hut
7. Healthcare Web Site Expands Reach to Pharmacy Industry
8. Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc.
9. URL Pharma Expands Colcrys(R) Patient Assistance Program
10. HIV Vaccine Strategy Expands Immune Responses
11. Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... IL (PRWEB) , ... February 06, 2016 , ... ... recovery phases of eating disorder treatment helps to reduce the frequency and level ... of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):